According to our (Global Info Research) latest study, the global Sacituzumab Tirumotecan market size was valued at US$ 206 million in 2025 and is forecast to a readjusted size of US$ 936 million by 2032 with a CAGR of 16.7% during review period.
Sacituzumab Tirumotecan is an antibody–drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP-2). It consists of a humanized monoclonal antibody, a cleavable linker, and a cytotoxic payload. The antibody component specifically recognizes and binds to the TROP-2 antigen expressed on tumor cells, enabling the targeted delivery of the cytotoxic agent into the cells, where the active component is released to inhibit DNA replication and induce cell death. This drug is mainly used for the targeted treatment of various solid tumors, such as breast cancer and lung cancer. It is characterized by high targeting specificity, strong cytotoxic efficacy, and relatively controllable systemic toxicity, making it an important innovative therapy in the field of antibody–drug conjugates.In 2025, global sacituzumab tirumotecan production reached approximately 1.2 million units.
Sacituzumab Tirumotecan, as a TROP-2-targeting antibody–drug conjugate (ADC), is in a rapid growth phase within the precision oncology market. With the rising incidence of high-prevalence solid tumors such as breast cancer and lung cancer, along with the increasing demand for targeted therapies, this drug is gradually gaining clinical recognition and driving market expansion due to its advantages of “high targeting specificity and potent cytotoxicity.” Meanwhile, the maturation of ADC technology platforms and supportive policies for innovative drugs have also facilitated its commercialization. However, market competition is intensifying, including from products with the same target (such as Trodelvy) as well as other ADC drugs (such as Enhertu), which pose direct competitive pressure. Overall, the market for Sacituzumab Tirumotecan represents a “high-value, fast-growing” segment of innovative therapeutics, with future growth mainly driven by indication expansion, global market development, and continuous validation of clinical data.
This report is a detailed and comprehensive analysis for global Sacituzumab Tirumotecan market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Sacituzumab Tirumotecan market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Sacituzumab Tirumotecan market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Sacituzumab Tirumotecan market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Sacituzumab Tirumotecan market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Sacituzumab Tirumotecan
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Sacituzumab Tirumotecan market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Kelun-Biotech, Merck & Co, Sichuan Kelun Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Sacituzumab Tirumotecan market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Monoclonal Antibody, mAb
Bispecific Antibody, bsAb
Market segment by Specification
60 mg/vial
120 mg/vial
Market segment by Production Technology
Innovator
Generic
Market segment by Dosage Form
Lyophilized Powder for Injection
Injection Solution
Market segment by Application
Breast Cancer
Lung Cancer
Digestive System Tumors
Others
Major players covered
Kelun-Biotech
Merck & Co
Sichuan Kelun Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Sacituzumab Tirumotecan product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Sacituzumab Tirumotecan, with price, sales quantity, revenue, and global market share of Sacituzumab Tirumotecan from 2021 to 2026.
Chapter 3, the Sacituzumab Tirumotecan competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Sacituzumab Tirumotecan breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Sacituzumab Tirumotecan market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Sacituzumab Tirumotecan.
Chapter 14 and 15, to describe Sacituzumab Tirumotecan sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Sacituzumab Tirumotecan. Industry analysis & Market Report on Sacituzumab Tirumotecan is a syndicated market report, published as Global Sacituzumab Tirumotecan Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Sacituzumab Tirumotecan market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.